BioMedPartners

What BioMedPartners does

BioMedPartners is a Swiss early-stage venture capital firm founded in 2002 in Basel, focusing exclusively on Life Sciences investments. The firm invests at Seed and Series A stages in biotech companies developing innovative therapeutics for high-unmet medical needs, with a primary geographic focus on the DACH region (Switzerland and Germany) and broader continental European coverage including France, Netherlands, and Belgium. BioMedPartners was succeeded by BiomedVC in 2021, and the combined entity has raised more than CHF 350 million across three predecessor funds (BioMedInvest I through III) and is currently raising BiomedInvest IV following an initial closing. BioMedPartners has been one of the first early-stage VCs in continental Europe to focus exclusively on Life Sciences, enabling the transformation of European academic discoveries into venture-backed biotech companies.

The firm generates returns through equity investments in portfolio companies, realizing gains via trade sales, IPOs, and secondary transactions. Notable exits include Cardior Pharmaceuticals (€1.025 billion to Novo Nordisk in 2024), Yellow Jersey Therapeutics / NM26 (approximately USD 1.25 billion to Johnson & Johnson in 2024), Tubulis (acquired by Gilead in April 2026), AMAL Therapeutics (up to €425 million to Boehringer Ingelheim in 2019), and NBE-Therapeutics (acquired by Boehringer Ingelheim in 2021). The portfolio spans oncology, rare diseases, cardiovascular, neurological disorders, and infectious diseases, with deal flow sourced primarily from academic institutions including ETH Zurich, University of Basel, University of Zurich, Hannover Medical School, and other European research centers.

The firm operates with a lean team of 9 management members plus 5 venture partners and 2 entrepreneurs in residence. Management combines former senior pharmaceutical R&D executives (notably from Roche and Novartis-affiliated entities), PhD scientists from leading institutions (ETH Zurich, Rockefeller University, Stanford), and experienced biotech entrepreneurs with successful prior exits. The combined BioMedPartners/BiomedVC brand carries more than 20 years of operating history and an institutional network across academic, pharma, and VC ecosystems in Europe.

Name

BioMedPartners

Legal name

BiomedVC AG

Website

http://www.biomedvc.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

BioMedPartners, succeeded by BiomedVC in 2021, is a Swiss early-stage life sciences venture capital firm founded in 2002 in Basel. The firm invests at Seed and Series A stages in biotech companies developing innovative therapeutics across the DACH region and broader continental Europe.

Ownership category

akta.pro rank

Product category

Investment Management

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI)

akta.pro secondary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Venture capital
• Life sciences
• Biotech investing
• Early stage funding
• Healthcare ventures

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Others

Revenue model

1. Venture Capital Fund Management: BioMedPartners generates returns through equity investments in early-stage biotech companies. Returns are realized through trade sales, IPOs, and secondary transactions. The predecessor raised more than CHF 350 million across three funds (BioMedInvest I through III) and is currently in the harvesting phase of its portfolio. BiomedVC is raising a new fund (BiomedInvest IV) which has already achieved an initial closing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

No source material was provided in the input to characterize BioMedPartners' core offerings.

Product overview

BioMedPartners is a Swiss early-stage venture capital firm focused exclusively on Life Sciences investments. Founded in 2002, it operates as a predecessor to BiomedVC and has raised more than CHF 350 million across three funds (BioMedInvest I through III). The firm specializes in investing in seed and Series A stage biotech companies developing innovative therapeutics for high-unmet medical needs, with a geographic focus on continental Europe, particularly the DACH region (Switzerland and Germany). BioMedPartners enables European scientific discoveries from academic labs to be transformed into venture-backed biotech companies, providing capital, expertise, and partnership support to first-time teams and experienced founders.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Multiple billion-euro exits including Cardior (€1.025B to Novo Nordisk), Yellow Jersey Therapeutics ($1.25B to J&J), and AMAL Therapeutics (up to €425M to Boehringer Ingelheim)
• +1 more outcomes

Named customers18 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Nine partnerships are on record, tiered minor and core.

• InnosuisseminorStrategic or Co-development PartnerMichael Wacker coaches startups in Switzerland for Innosuisse, the Swiss governmental commission for technology and innovation. Also supports Innosuisse Innovation Projects and SNF BRIDGE Proof of Concept Fellows.
• University of StrasbourgcoreStrategic or Co-development PartnerALENTIS Therapeutics is a spin-out from the University of Strasbourg, developing novel therapeutics for advanced liver disease and cancer.
• Hannover Medical SchoolcoreStrategic or Co-development PartnerCardior Pharmaceuticals is a spin-off from Hannover Medical School, focusing on non-coding RNA based therapeutics for heart failure.
• University of Zurich and University of BaselcoreStrategic or Co-development PartnerImmunOs Therapeutics is a spin-off from University of Zurich and University of Basel, developing novel human immunomodulatory proteins for cancer treatment.
• ETH ZurichcoreStrategic or Co-development PartnerMultiple portfolio companies are ETH Zurich spin-offs including TOLREMO Therapeutics, Inositec, and Numab Therapeutics. The firm maintains strong relationships with ETH for sourcing academic spin-out opportunities.
• Netherlands Cancer Institute and Oxford UniversitycoreStrategic or Co-development PartnerScenic Biotech is a spin-out from Netherlands Cancer Institute and Oxford University, applying Cell-Seq platform technology.
• Vrije Universiteit Brussel (VUB)coreStrategic or Co-development PartnerPRECIRIX is a spin-off from VUB, developing new radiopharmaceuticals for cancer treatment.
• Biozentrum, University of BaselcoreStrategic or Co-development PartnerNXI Therapeutics is a spin-out from Biozentrum, University of Basel, focusing on T cell-mediated autoimmune conditions.
• RocheminorStrategic or Co-development PartnerNoema Pharma in-licensed four therapeutic products from Roche for orphan neurological disorders treatment.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Forbion: Forbion is a leading European life sciences venture capital firm investing in early- and late-stage biotech companies developing therapeutics; directly comparable to BioMedPartners as a specialist European biotech VC backing therapeutic platforms across the DACH/Benelux region.
• Sofinnova Partners: Sofinnova Partners is one of Europe's oldest life sciences VCs focused on biotech and medtech, with a DACH-adjacent base and a comparable model of backing early-stage European life sciences startups to exit via pharma M&A or IPO.
• TVM Capital Life Sciences: TVM Capital Life Sciences is a European/Cross-Atlantic life sciences VC with comparable early-stage therapeutic focus, particularly in European biotechs developing innovative drugs; competes for the same DACH/Benelux deal flow as BioMedPartners.
• Wellington Partners: Wellington Partners is a Munich-based European technology and life sciences VC with comparable early-stage biotech investment activity, particularly in Germany and Switzerland, and similar focus on therapeutics and platform companies.
• Atlas Venture: Atlas Venture is a leading global early-stage biotech VC building companies from inception; comparable to BioMedPartners in its exclusive focus on early-stage therapeutic biotech creation and its seed/Series A model.
• Medicxi: Medicxi is a European biotech VC focused on investing in and creating early-stage therapeutic companies, often out of pharma assets or academic science; closely mirrors BioMedPartners' seed/Series A biotech model in Europe.
• Kurma Partners: Kurma Partners is a Paris-based European healthcare VC with comparable early-stage biotech focus, operating in adjacent continental European geographies (France/Benelux/DACH) and competing for similar therapeutic assets.
• Creathor Ventures: Creathor Ventures is a German/European early-stage technology and life sciences VC based in Bad Homburg, directly comparable to BioMedPartners in DACH early-stage biotech investment (Aristotelis Nastos was previously a Partner at Creathor).
• MPM Capital: MPM Capital is a US- and Europe-based biotech VC with deep life sciences focus; comparable to BioMedPartners' model of building therapeutic companies from inception (Markus Hosang was previously a Venture Partner at MPM managing the European office).

Broad incumbents

• Novo Ventures: Novo Ventures (Novo Holdings) is a large global life sciences investor with significant European biotech exposure; broader incumbent with a larger fund base but operating in the same European biotech VC space and acquiring comparable therapeutic assets (e.g., Cardior via Novo Nordisk).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biomedpartners

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments88 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioMedPartners